Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Fig. 3

Metabolic and safety outcomes with semaglutide vs placebo by baseline metformin use. Figure compares semaglutide with placebo. Data-points are proportional to subgroup size. For change in metabolic outcomes, analyses were based on a mixed model for repeated measurements at week 80 (SUSTAIN 6) or week 83 (PIONEER 6), with treatment by subgroup adjusted for baseline value and trial nested within visits. For the safety analyses, number of events per 100 patient-years were analyzed using a negative binomial regression model with a log link and the logarithm of the observation time (100 years) as offset, with treatment by subgroup as fixed factors adjusted by trial. Dashed vertical lines represent lines of null effect (0 for ETDs and 1 for ERRs). ETD/ERR is for semaglutide vs placebo. *Defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or to perform other resuscitative actions. n-numbers are based on the FAS; the number of subjects included for each analysis was smaller according to data availability.  AE adverse event, CI confidence interval, ERR estimated risk ratio, ETD estimated treatment difference, FAS full analysis set, HbA1c glycated hemoglobin, MET metformin, R events per 100 patient-years observed

Back to article page